Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s145934
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Prospects for Cisplatin and Nab-Paclitaxel Combination Therapy in Patients With Pre-Treated Triple-Negative Breast Cancer. Description of the Clinical Case.

Medical Council
2018English

Cisplatin in Combination With Zoledronic Acid: A Synergistic Effect in Triple-Negative Breast Cancer Cell Lines

International Journal of Oncology
Cancer ResearchOncology
2013English

A microRNA Signature Associated With Pathological Complete Response to Novel Neoadjuvant Therapy Regimen in Triple-Negative Breast Cancer

Tumor Biology
MedicineCancer Research
2017English

Pathological Response in a Triple Negative Breast Cancer Cohort Treated With Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Clinical Cancer Research
Cancer ResearchOncology
2018English

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

Frontiers in Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy